Crely
Crely is a MedTech company dedicated to reducing surgical site infection rates after surgery and improving health outcomes and patient experience through innovative AI-based early warning systems and wearable medical devices for continuous monitoring of patient biomarkers.
Industries
Nr. of Employees
small (1-50)
Products
AI-based early warning system for surgical site infection (wearable sensor + analytics + app)
An integrated system combining a non-invasive wearable sensor, mobile application, secure EHR integration, and AI/ML analytics to detect and predict postoperative surgical site infections for early clinical intervention.
AI-based early warning system for surgical site infection (wearable sensor + analytics + app)
An integrated system combining a non-invasive wearable sensor, mobile application, secure EHR integration, and AI/ML analytics to detect and predict postoperative surgical site infections for early clinical intervention.
Services
Clinical assessment and validation workflows to evaluate monitoring solutions for detecting surgical site infections and supporting clinical adoption.
Integration of continuous biomarker and vital-signs data into existing EHR systems using open-standard communication to enable clinician workflows.
Support for QMS setup, regulatory strategy development, and preparation for device approvals across regions, informed by experience with ISO 13485 auditing and regulatory submissions.
Clinical assessment and validation workflows to evaluate monitoring solutions for detecting surgical site infections and supporting clinical adoption.
Integration of continuous biomarker and vital-signs data into existing EHR systems using open-standard communication to enable clinician workflows.
Support for QMS setup, regulatory strategy development, and preparation for device approvals across regions, informed by experience with ISO 13485 auditing and regulatory submissions.
Expertise Areas
- Digital health
- Remote patient monitoring
- Surgical site infection detection and prediction
- Medical device product development
Key Technologies
- Wearable biomarker sensors
- Remote patient monitoring systems
- Mobile digital health applications
- AI / machine learning for predictive analytics
News & Updates
1 in 10 patients get an infection while receiving care. More than 50% of surgical site infections can be antibiotic-resistant.
Health care–associated infections (HAIs) account for a large proportion of the harms caused by health care and are associated with high costs. Surgical site infections contribute significantly to overall costs, with a total annual cost of $9.8 billion.
SSI is a leading cause of readmissions, with rates ranging from 1.45% to 6.34% among patients at various hospitals.
The incidence of 30-day readmission following primary TKA from 2012 to 2016 was 3.19%.
Wound infection after Cesarean Section was 8.9% during a 30-day follow-up, though only 1.8% at hospital discharge.
Early detection of SSI may improve outcomes; previous models only consider baseline risk factors, not the wound itself.
1 in 10 patients get an infection while receiving care. More than 50% of surgical site infections can be antibiotic-resistant.
Health care–associated infections (HAIs) account for a large proportion of the harms caused by health care and are associated with high costs. Surgical site infections contribute significantly to overall costs, with a total annual cost of $9.8 billion.
SSI is a leading cause of readmissions, with rates ranging from 1.45% to 6.34% among patients at various hospitals.
The incidence of 30-day readmission following primary TKA from 2012 to 2016 was 3.19%.
Wound infection after Cesarean Section was 8.9% during a 30-day follow-up, though only 1.8% at hospital discharge.
Early detection of SSI may improve outcomes; previous models only consider baseline risk factors, not the wound itself.